LINC02636: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02636

NCBI ID: G102723350

LINC02636

Other Name(s): Long intergenic non-protein coding RNA 2636, transcript variant X3 | long intergenic non-protein coding RNA 2636 | LINC02636 variant X3

LINC02636: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02636 is a long intergenic non-protein-coding RNA (lncRNA) with a length of approximately 220 nucleotides. It is found in various tissues and cells of the human body, including the brain, heart, and liver. LINC02636 is a non-coding RNA that can interact with other non-coding RNAs (ncRNAs) and cause the translation of specific genes into proteins.

The discovery of LINC02636

The LINC02636 gene was first identified using bioinformatics tools to search for potential non-coding RNAs in the human genome. The gene was later cloned and sequenced to confirm its existence. LINC02636 is a part of a larger non-coding RNA family known as the LINC0260 family, which has been identified in various organisms, including humans.

Expression of LINC02636

LINC02636 is a highly expressed gene in the human body, with the highest expression levels in the brain, heart, and liver. It is also expressed in other tissues, including the blood cells and the placenta. LINC02636 is expressed in a variety of cell types, including neurons, astrocytes, endothelial cells, and immune cells.

The function of LINC02636

The function of LINC02636 is not well understood, but it is involved in various cellular processes. LINC02636 has been shown to interact with other non-coding RNAs, including PRDM1, PRDM2, and HIF1?±. PRDM1 and PRDM2 are RNA-protein complexes that are involved in the regulation of gene expression, while HIF1?± is a key regulator of the hypoxic response.

LINC02636 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. It has been shown to promote the growth of cancer cells and to contribute to the development of neurodegenerative diseases.

Drug targeting LINC02636

The potential drug targeting of LINC02636 is due to its unique function as a non-coding RNA. LINC02636 can interact with other non-coding RNAs and cause the translation of specific genes into proteins. This property makes LINC02636 an attractive target for small molecules that can modulate its function.

One of the most promising compounds that has been shown to interact with LINC02636 is curcumin, an anti-inflammatory compound that is commonly used in food and medicine. Curcumin has been shown to inhibit the activity of LINC02636 and to reduce its expression levels in various cellular models.

Another compound that has been shown to interact with LINC02636 is the small molecule drugletrepan, which is a peptide that can inhibit the activity of PRDM1 and PRDM2. The drugletrepan has been shown to reduce the activity of LINC02636 and to inhibit its translation into proteins.

Biomarker potential

The potential use of LINC02636 as a biomarker for disease diagnosis and treatment is an exciting area of research. LINC02636 has been shown to be involved in various cellular processes that are related to disease development, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the most promising applications of LINC02636 as a biomarker is its potential to diagnose and

Protein Name: Long Intergenic Non-protein Coding RNA 2636

The "LINC02636 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02636 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets